Comparative Pharmacology
Head-to-head clinical analysis: SULFA TRIPLE 2 versus SULFALOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFA TRIPLE 2 versus SULFALOID.
SULFA-TRIPLE #2 vs SULFALOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The sulfonamides (sulfamethazine, sulfathiazole, sulfamerazine) act as competitive inhibitors of para-aminobenzoic acid (PABA) utilization in bacterial dihydrofolate synthesis, thereby inhibiting folic acid synthesis and bacterial growth.
Sulfaloid is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production in susceptible bacteria.
2 tablets orally every 4 hours initially, then 2 tablets every 6 hours thereafter. Each tablet contains 167 mg sulfadiazine, 167 mg sulfamerazine, and 167 mg sulfamethazine (total sulfonamide 500 mg per tablet).
500 mg orally every 12 hours for 7-10 days.
None Documented
None Documented
Sulfadiazine: 10-16 hours; Sulfamerazine: 15-24 hours; Sulfamethazine: 12-24 hours. The combined half-life is approximately 15-20 hours in patients with normal renal function, requiring dosing every 12-24 hours.
Terminal elimination half-life: 6-8 hours in adults with normal renal function (ClCr >90 mL/min); prolonged to 12-20 hours in moderate renal impairment (ClCr 30-50 mL/min) and >30 hours in severe renal impairment (ClCr <30 mL/min).
Renal (approximately 70-80% as unchanged sulfonamides via glomerular filtration and tubular secretion); biliary/fecal (approximately 20-30% as metabolites).
Renal: 70% (unchanged via glomerular filtration and tubular secretion); Biliary/fecal: 20% (conjugated metabolites); 10% metabolized in liver to inactive acetylated derivatives.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)